Citigroup Lowers Krystal Biotech (NASDAQ:KRYS) Price Target to $155.00

Krystal Biotech (NASDAQ:KRYS) had its target price decreased by Citigroup from $215.00 to $155.00 in a research note issued to investors on Friday morning,Benzinga reports. Citigroup currently has a neutral rating on the stock.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reissued a “buy” rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Finally, Guggenheim decreased their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $211.13.

Krystal Biotech Stock Up 0.2%

KRYS opened at $130.60 on Friday. The firm has a market capitalization of $3.77 billion, a P/E ratio of 43.68 and a beta of 0.79. The stock’s 50 day moving average price is $166.74 and its two-hundred day moving average price is $168.61. Krystal Biotech has a 12-month low of $127.40 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. As a group, analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

Several institutional investors have recently bought and sold shares of the stock. Crossmark Global Holdings Inc. boosted its stake in Krystal Biotech by 2.7% in the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company’s stock valued at $427,000 after buying an additional 63 shares in the last quarter. US Bancorp DE boosted its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after buying an additional 82 shares in the last quarter. Xponance Inc. boosted its stake in Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company’s stock valued at $338,000 after buying an additional 88 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its stake in Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company’s stock valued at $273,000 after buying an additional 95 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).